Year archive

ALK-Abelló — 2026 filings

All 23 regulatory filings released by ALK-Abelló (ALK) in 2026, sourced directly from the official regulator.

23 Filings

2026 Period

2026 filings (23)

Filing	Released	Lang
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-06-01	Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-06-01	Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-06-01	English
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-06-01	English
ALK upgrades its full-year outlook Earnings Release Q1 2026	2026-05-04	Danish
ALK upgrades its full-year outlook Capital/Financing Update	2026-05-04	Danish
ALK upgrades its full-year outlook Capital/Financing Update	2026-05-04	English
ALK upgrades its full-year outlook Capital/Financing Update	2026-05-04	English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy Regulatory Filings	2026-04-20	Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy Regulatory Filings	2026-04-20	Danish
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy Regulatory Filings	2026-04-20	English
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy Regulatory Filings	2026-04-20	English
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-04-08	Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-04-08	Danish
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-04-08	English
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff Director's Dealing	2026-04-08	English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin Annual Report (ESEF) FY 2025	2026-02-20	English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin Annual Report FY 2025	2026-02-20	English
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin Earnings Release FY 2025	2026-02-20	English
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Regulatory Filings	2026-01-29	Danish
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Regulatory Filings	2026-01-29	Danish
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Regulatory Filings	2026-01-29	English
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children Regulatory Filings	2026-01-29	English

Filings by year

2026 23 filings
2025 47 filings
2024 64 filings
2023 41 filings
2022 53 filings
2021 67 filings
2020 43 filings
2019 74 filings
2018 44 filings
2017 120 filings
2016 116 filings
2015 46 filings
2014 68 filings
2013 64 filings
2012 142 filings
2011 62 filings
2010 50 filings
2009 30 filings
2008 34 filings
2007 26 filings